文献速递白血病

吉瑞替尼在既往接受强化化疗和米哚妥林治疗的难治或复发FLT3突变急性髓系白血病患者中的活性:法国AML协作组ALFA/FILO的一项研究

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
PubMed 文献 · Leukemia · 2022-11-14

这项双向性研究纳入167例复发/难治FLT3突变急性髓系白血病患者,其中140例接受吉瑞替尼单药治疗(队列B),67例既往接受过强化化疗和米哚妥林(队列C)。队列B和C的复合完全缓解率(排除造血干细胞移植后出现者)分别为25.4%和27.5%,中位总生存期分别为6.4个月和7.8个月。多因素分析显示女性(HR 1.61)、不良细胞遗传学风险(HR 2.52)和吉瑞替尼后异基因造血干细胞移植(HR 0.13)与总生存期相关。

要点

  • 队列B和C的复合完全缓解率(排除HSCT后出现者)分别为25.4%和27.5%,中位OS分别为6.4和7.8个月。
  • 与ADMIRAL试验相比,本研究ECOG≥2者83.6% vs 16.6%,FLT3-TKD突变21.0% vs 8.5%。
  • 多因素分析:女性HR 1.61,不良细胞遗传学风险HR 2.52,吉瑞替尼后异基因HSCT HR 0.13。

核心结论

  • 尽管这些患者既往治疗更重,这些真实世界数据再现了ADMIRAL的结果,并为既往接受强化化疗和米哚妥林治疗及超过二线治疗的患者提供了新见解,这些患者可从门诊治疗中获益。

研究设计与样本

  • 这是一项双向性研究,纳入167例复发/难治FLT3突变急性髓系白血病患者。
  • 其中140例接受吉瑞替尼单药治疗(队列B),包括67例既往接受过强化化疗和米哚妥林治疗者(队列C)。

主要发现

  • 队列B和C的复合完全缓解率(排除造血干细胞移植后出现者)分别为25.4%和27.5%。
  • 队列B和C的中位总生存期分别为6.4个月和7.8个月。
  • 与ADMIRAL试验相比,本研究患者特征主要差异为ECOG≥2(83.6% vs 16.6%)、FLT3-TKD突变(21.0% vs 8.5%)、原发诱导失败(15.0% vs 40.0%)和治疗线数超过二线(37.1% vs 0.0%)。
  • 多因素分析中与总生存期相关的预后因素包括女性(HR 1.61)、不良细胞遗传学风险(HR 2.52)和吉瑞替尼后异基因造血干细胞移植(HR 0.13)。

临床怎么用

  • 作者指出,这些真实世界数据再现了ADMIRAL的结果,并为既往接受强化化疗和米哚妥林治疗及超过二线治疗的患者提供了新见解,这些患者可从门诊治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive chemotherapy and midostaurin (cohort C). The main differences in patient characteristics in this study compared to the ADMIRAL trial were ECOG ≥ 2 (83.6% vs. 16.6%), FLT3-TKD mutation (21.0% vs. 8.5%), primary induction failure (15.0% vs. 40.0%) and line of treatment (beyond 2nd in 37.1% vs. 0.0%). The rates of composite complete remission, excluding those that occurred after hematopoietic stem cell transplantation (HSCT), were similar at respectively 25.4% and 27.5% in cohorts B and C. Median overall survival (OS) for these two groups was also similar at respectively 6.4 and 7.8 months. Multivariate analyses for prognostic factors associated with OS identified female gender (HR 1.61), adverse cytogenetic risk (HR 2.52), and allogenic HSCT after gilteritinib (HR 0.13). Although these patients were more heavily pretreated, these real-world data reproduce the results of ADMIRAL and provide new insights into the course of patients previously treated by intensive chemotherapy and midostaurin and beyond the 2nd line of treatment who can benefit from treatment in an outpatient setting.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dumas PY, Raffoux E, Bérard E, et al. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia. 2022. PMID: 36376378. doi:10.1038/s41375-022-01742-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。